Novavax's COVID-19 Vaccine Wins FDA AdCom Blessing, Removing 'Major Overhang'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall St set to fall at open as yields and oil rebound; Fed minutes in focus
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Musk rules out TSMC role in Terafab operations; Intel gains
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- HubSpot to cut 7% of workforce in restructuring plan
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
Argus Reiterates Buy Rating on Moderna (MRNA), 'Discounted price offers buying opportunity'
June 9, 2022 11:09 AM EDTArgus analyst John Eade reiterated a Buy rating and $180.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "We are maintaining our BUY rating on Focus List selection Moderna Inc. (NYSE: MRNA). The company develops therapeutics and... More
Novavax's (NVAX) Covid-19 Vaccine Approval in the U.S. Could Be Delayed - CNBC
June 9, 2022 10:16 AM EDTThe U.S. Food and Drug Administration's (FDA) decision on Novavax's (NASDAQ: NVAX) Covid-19 vaccine could be delayed, according to a report by CNBC.
An FDA spokesperson told CNBC that the regulatory body will have to review modifications to the drugmakers... More



